• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Ocular Therapeutix dry eye treatment trial fails to meet primary endpoint

October 22, 2021 By Sean Whooley

Ocular Therapeutix logoOcular Therapeutix (NSDQ:OCUL) announced today that its Phase 2 clinical trial for treating dry eye disease (DED) did not meet its primary endpoint.

Bedford, Massachusetts-based Ocular Therapeutix’s U.S.-based, randomized, double-masked, multi-center, vehicle-controlled Phase 2 clinical trial evaluated OTX-CSI (cyclosporine intracanalicular insert) for treating DED by measuring signs and symptoms of DED in 140 subjects treated in both eyes over approximately 16 weeks.

The study did not demonstrate separation between the OTX-CSI-treated subjects and the vehicle-treated subjects for the primary endpoint of increased tear production at 12 weeks, according to a news release.

Ocular Therapeutix’s study did observe an improvement compared with baseline in signs of dry eye starting as early as two weeks after insertion and continuing over the 12-week study period. However, those improvements were not statistically significant compared with the vehicle insert.

Overall, the OTX-CSI insert was observed to have a favorable safety profile and was well tolerated with no ocular serious adverse events. The most common ocular adverse event was ocular pruritus, which was seen in less than 16% of subjects.

“We would like to thank the patients and investigators who participated in the OTX-CSI clinical trial,” Ocular Therapeutix President and CEO Antony Mattessich said in the release. “While we are disappointed by these results, demonstrating clinical benefit in patients with dry eye disease remains a significant unmet need and we will continue to review the data for additional information that may inform future development of this program. We remain confident in the potential of our hydrogel-based formulation technology and its ability to deliver innovative ophthalmology therapies. We look forward to our anticipated Phase 2 top-line read out for OTX-DED for the short-term treatment of signs and symptoms of dry eye disease.

“In addition, we expect to provide updates on other pipeline programs being developed to treat glaucoma and wet-AMD as well as updates on our currently marketed product, Dextenza, which recently received FDA approval to expand its label for the treatment of ocular itching associated with allergic conjunctivitis.”

Filed Under: Clinical Trials, Drug-Device Combinations, Featured, Optical/Ophthalmic Tagged With: Ocular Therapeutix

IN CASE YOU MISSED IT

  • Breaking: Sequel to launch twiist automated insulin delivery system next month
  • Dexcom shares U.S. report on CGM benefits for type 2 diabetes
  • Study backs Tandem automated insulin delivery in pregnant women with type 1 diabetes
  • Data backs Medtronic MiniMed 780G for type 2, children as company seeks expanded indications
  • Abbott could pave new roads in diabetes management with dual sensor on the horizon

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at swhooley@wtwhmedia.com.

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS